Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190957 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT00190957 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 140 participants.
The verdict
NCT00190957, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
Interventions
- DRUG placebo
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190957
The ClinicalTrials.gov registry entry for NCT00190957 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00190957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190957 about?
NCT00190957 is a clinical study titled "Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse". Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
What is the current status of trial NCT00190957?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2004-08. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00190957?
The interventions under investigation include: placebo (DRUG), Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00190957?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.